Table 2.
Results at 16 weeks.
| Variable | LDA-UVB (n = 33) | HDA cohort (n = 31) | P value |
|---|---|---|---|
| Mean final PGA score (range) | 1.36 (0, 4) | 1.77 (range 0-4) | 0.09 |
| Final PGA scores of 0-1 (%) | 21 (63.6%) | 12 (38.7%) | 0.04 |
| Median final DLQI score (range) | 7 (1, 11) | 8 (2, 15) | 0.01 |
| Number (%) reporting >50% reduction in final DLQI score | 15 (45.4%) | 12 (48.4%) | 0.11 |
| Adverse effect of any type (%) | 13 (39.4%) | 23 (74.2%) | 4.8 × 10–5 |
| Headache (%) | 2 (6.1%) | 11 (35.5%) | 4.0 × 10–3 |
| Elevated cholesterol (%) | 2 (6.1%) | 8 (25.8%) | 0.03 |
| Dry lips (%) | 2 (6.1%) | 8 (25.8%) | 0.03 |
Abbreviations: DLQI, dermatology life quality index; HDA, high dose alitretinoin; LDA-UVB , low-dose alitretinoin with narrowband UVB therapy; PGA, physician’s global assessment.
Wilcoxon rank sum test was used to compare continuous or nominal variables and Fisher’s exact test used to compare categorical data between the LDA-UVB and HDA groups.